In conclusion, this study demonstrates that Smteg treatment in an experimental model of airway inflammation induced by OVA reduces eosinophils in BAL and lung tissue, as well as tissue damage, specific anti-OVA IgE and IL-5, IL-13, IL-25 and CCL11 levels in lungs, diminishing overall airway pathology. This evidence concerns the gene IL5 and inflammatory response.